Firm intentionHealthcare10 November 2026

BioNTech US Inc. to acquire a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
BioNTech US Inc.
Target
Rare Pediatric Disease Priority Review Voucher of Scholar Rock Inc.
Deal value
USD 205,000,000
Announced
10 November 2026
Status
Firm intention
Sector
Healthcare
Country
United States
Consideration
cash
What we know

BioNTech US Inc. has agreed to buy a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc. for $205 million in cash. Scholar Rock Inc. is a wholly owned subsidiary of Scholar Rock Holding Corporation, which disclosed the agreement in a Form 8-K dated November 10, 2026. This is a purchase of a single asset, not an acquisition of the company or its shares.

The parties signed the asset purchase agreement on November 9, 2026. The FDA awarded the voucher to Scholar Rock on September 11, 2026, when it approved the biologics license application for ISEMBYLD (apitegromab-mstn). The 8-K reported the agreement under Item 1.01 alongside the company's third-quarter 2026 results.

BioNTech US will pay the full $205 million in cash when the sale closes. The agreement includes customary representations, warranties, covenants and indemnification provisions, subject to certain limitations.

Closing remains subject to customary conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Scholar Rock Holding Corporation said it will file the full agreement with its Annual Report on Form 10-K for the year ended December 31, 2026.

Deal timeline

1 update
  1. Firm intention

    BioNTech US Inc. firm intention to acquire Scholar Rock Inc.

    Item 1.01 Entry into a Material Definitive Agreement. On November 9, 2026, Scholar Rock Holding Corporation’s (the “Company”) wholly owned subsidiary Scholar Rock Inc. (“Scholar Rock”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”) with BioNTech US Inc. (“Buyer”) pursuant to which Scholar Rock agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) to

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Buyer history

BioNTech US Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive